Sudarshan Pharma Industries Board Meeting Scheduled on May 22, 2026 to Consider Migration from SME Platform to Main Board

Sudarshan Pharma Industries Limited has notified the stock exchange of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026. The intimation was filed on May 18, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda: Key Proposals

The board meeting has been convened to consider and approve several significant corporate actions, all subject to shareholders' approval. The agenda items reflect a major step in the company's capital market journey, centered on upgrading its listing status.

The following key proposals are scheduled to be considered at the meeting:

Agenda Item: Details Migration — BSE SME to BSE Main Board: Consider and approve migration of listing/trading of equity shares from SME Platform of BSE Limited to Main Board of BSE Limited Listing on NSE Main Board: Consider and approve making application for listing/trading of equity shares on the Main Board of National Stock Exchange of India Limited (NSE) Postal Ballot Notice & Calendar: Consider and approve Postal Ballot Notice and calendar of events to seek member approval for migration and other incidental matters

Migration from SME Platform to Main Board

The primary agenda of the board meeting is to deliberate on the migration of Sudarshan Pharma Industries' equity shares from the SME Platform of BSE Limited to the Main Board of BSE, as well as to initiate the process for listing on the Main Board of NSE. Both proposals are subject to shareholders' approval, which the company intends to seek through a Postal Ballot process.

The board will also approve the Postal Ballot Notice along with the calendar of events for conducting the shareholder voting process. This includes approval for migration-related matters and other incidental items connected to the transition.

Filing Details

The intimation was signed by Sachin Mehta, Joint Managing Director of Sudarshan Pharma Industries Limited, and addressed to the Listing Department of BSE Limited. The communication was filed under reference number SPIL/CS/SE/2026-2027/17, dated May 18, 2026.

Sudarshan Pharma Industries Limited has filed a revised disclosure with BSE Limited in response to a query raised by the exchange seeking clarification on the commencement and conclusion time of the Board of Directors meeting held on May 15, 2026. The company confirmed that the board meeting commenced at 9:00 am and concluded at 9:30 am. The revised announcement was filed by Joint Managing Director Sachin Mehta on May 18, 2026, reaffirming all resolutions passed at the earlier meeting.

Board Approvals at a Glance

The board considered and approved several key resolutions at its May 15, 2026 meeting. The following table summarises the key decisions taken:

Parameter: Details Security Type: 8.00% Senior Unsecured Foreign Currency Convertible Bonds (FCCBs) Issue Size: Up to USD 20 million (in one or more tranches) Maturity: Due 2029 (3 years and 2 months from date of full payment) Coupon Rate: 8% per annum Issue Opening Date: May 18, 2026 Relevant Date: May 15, 2026 Regulatory Floor Price: Rs.30.19 per share Offering Circular Date: On or about May 15, 2026 Type of Issuance: International offering Allotment Timeline: Within 60 days from the Issue Closing Date Board Meeting Commencement: 9:00 am Board Meeting Conclusion: 9:30 am

The board also approved the draft Offering Circular dated on or about May 15, 2026, and designated May 15, 2026 as the 'Relevant Date' for the purpose of the FCCB issue, in accordance with the Issue of Foreign Currency Convertible Bonds and Ordinary Shares (Through Depository Receipt Mechanism) Scheme, 1993, as amended.

Conversion and Pricing Details

The FCCB issuance carries significant equity conversion implications. The following table presents the key financial and conversion parameters as disclosed:

Parameter: Details Issue Size (USD): Up to USD 20 million Conversion Rate Applied: USD 1 = Rs.95.93 Equivalent INR Amount: Rs.191.86 Crores Approximate Equity Shares on Conversion: ~6,35,50,845 equity shares of Re.1/- each Floor Price (Regulatory): Rs.30.19 per share Defaults on Coupon Payment: Nil

The number of equity shares on conversion has been calculated on the basis of the regulatory floor price of Rs.30.19, considering the issue size of up to USD 20 million equivalent to INR 191.86 Crores.

Authorised Signatories and Prior Approvals

The board has authorised Mr. Hemal Vasantra Mehta, Chairman & Managing Director, and/or Mr. Sachin Vasantra Mehta, Joint Managing Director, to sign all documents related to the FCCB issuance, including agreements, powers of attorney, undertakings, and indemnities, and to make any amendments to the documents before or after execution.

The FCCB issuance is backed by prior approvals at multiple levels. Shareholders of Sudarshan Pharma Industries had accorded their approval on August 11, 2025 for the proposed bond issuance. The company subsequently received an in-principle approval from BSE Limited dated September 25, 2025, paving the way for the board to formally deliberate and approve the matter. The final issuance remains subject to receipt of all applicable regulatory and statutory approvals as required under prevailing laws and exchange regulations.

Company Overview

Sudarshan Pharma Industries Limited is headquartered at 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai – 400092. The company's compliance correspondence can be directed to compliance@sudarshanpharma.com , and further information is available at www.sudarshanpharma.com .

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.